Informed Prostate Cancer Patient Support

Testosterone Treatment in Prostate Cancer Survivors With Hypogonadism: A Randomized Clinical Trial | Trials | JAMA Internal Medicine | JAMA Network IPCSG Newsletter — Clinical Update A review of the SPIRIT trial, the 2026 FDA/HHS label reconsideration, and where the guidelines now stand BLUF (Bottom Line Up Front):   For decades, a history of prostate cancer was treated as an almost automatic disqualifier for testosterone replacement therapy (TRT), regardless of how low-risk the cancer was or how long a man had been disease-free. That position was never based on a randomized trial — it was based on fear, extrapolated from the fact that androgen deprivation shrinks advanced prostate cancer. The first placebo-controlled randomized trial designed to actually test the question, the SPIRIT trial, has now reported results: 12 weeks of TRT in men with low-grade, organ-confined disease who were disease-free after radical prostatectomy produced zero cases of biochemical recu...

Study Warns on Sedentary Behavior and Cancer Mortality | MedPage Today IPCSG Newsletter · Research Digest Does Exercise Extend Life After a Prostate Cancer Diagnosis? What randomized trials, large cohort studies, and the newest 2025–2026 research actually show — and where the evidence still runs out. IPCSG Newsletter | July 2026 BLUF — Bottom Line Up Front Physical activity after a prostate cancer diagnosis is consistently associated with lower rates of death from prostate cancer and from all causes in large observational cohorts — with the biggest apparent benefit tied to vigorous activity (roughly 3+ hours a week) and to men who have had surgery rather than radiation. But no completed randomized controlled trial has yet proven that exercise causes longer survival specifically in prostate cancer, the way one now has in colon cancer (the CHALLENGE trial, NEJM , June 2025). The definitive prostate trial, INTERVAL‑GAP4, could not recruit enough men a...

Ac-225 rosopatamab tetraxetan shows promising activity in Lu-PSMA–pretreated mCRPC | Urology Times Advanced Therapy Watch Informed Prostate Cancer Support Group Newsletter — Advanced & Metastatic Disease Series BLUF (Bottom Line Up Front):   At the 2026 ASCO Annual Meeting, Convergent Therapeutics reported interim Phase 2 results from Part 3 of the CONVERGE-01 trial testing Ac-225 rosopatamab tetraxetan (CONV01-α), an alpha-particle-emitting radioantibody, in men with metastatic castration-resistant prostate cancer (mCRPC) whose disease had already progressed after Lu-177-PSMA radioligand therapy — a population with no established standard of care. Among 35 treated patients, 40% of those evaluable for PSA response achieved a decline of 50% or more, with the best durability seen at the intended Phase 3 target dose (median radiographic progression-free survival of 8.41 months). Side effects were mostly blood-count related and manageable; there was no kidney toxi...